Status:
RECRUITING
Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute
Collaborating Sponsors:
Instituto de Salud Carlos III
Conditions:
Migraine Disorders
Eligibility:
All Genders
18-45 years
Brief Summary
The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan. Participants will be asked...
Detailed Description
There is still an unmet need in acute migraine treatment, some patients don't respond properly to acute medication. There are some interindividual differences in clinical characteristics of migraine ...
Eligibility Criteria
Inclusion
- Migraine with or without aura diagnosis according to ICHD-3 criteria
- \<8 migraine days per month
- Be able to read, write and understand instructions.
- Have internet access and mail address
- Signing of the informed consent
Exclusion
- Active preventive treatment for migraine
- Active medication with an effect over the central nervous system
- Serious physical or psychiatric condition
- Cardiovascular or hepatic disease
- Pregnant or breastfeeding women
- Any triptan contraindication
- Severe migraine attacks without previous response to triptans or NSAIDs
Key Trial Info
Start Date :
January 25 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT06503848
Start Date
January 25 2024
End Date
December 1 2024
Last Update
October 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitari Vall d'Hebron
Barcelona, Spain